12 results match your criteria Annals of pancreatic cancer[Journal]

  • Page 1 of 1

Adding combination immunotherapy consisting of cancer vaccine, anti-PD-1 and anti-CSF1R antibodies to gemcitabine improves anti-tumor efficacy in murine model of pancreatic ductal adenocarcinoma.

Ann Pancreat Cancer 2019 Dec;2

Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Background: Immunotherapy can take advantage of the immunogenic response that chemotherapy elicits in tumors. Gemcitabine is a standard agent used in the treatment of pancreatic cancer, with known effects on the tumor immune microenvironment. The combination immunotherapy of the GVAX cancer vaccine, anti-PD-1 antibody and anti-CSF-1R antibody has been shown to improve survival in a murine model of metastatic pancreatic adenocarcinoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/apc.2019.11.01DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7220030PMC
December 2019

Analyzing outcomes of neoadjuvant and adjuvant treatment for borderline-resectable pancreatic adenocarcinoma in the perioperative period at an academic institution.

Ann Pancreat Cancer 2020 Mar 9;3. Epub 2020 Mar 9.

Department of Medicine, University of Arizona Cancer Center, Tucson, AZ, USA.

Background: Only 15-20% of pancreatic ductal adenocarcinoma (PDAC) patients are upfront surgical candidates at presentation, and for this cohort of patients, the 5-year survival is a mere 20% despite adjuvant therapy. Previous data indicate that in clinical practice most of these cases are "borderline-resectable," and there is currently no mature data on perioperative treatment.

Methods: We performed a retrospective electronic chart review of patients with "borderline-resectable"PDAC treated at an academic comprehensive cancer center, dividing them into groups based on surgery alone, surgery plus neoadjuvant, adjuvant, or neoadjuvant plus adjuvant perioperative treatment groups. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/apc.2020.02.01DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7170377PMC

Pitfalls of minimally invasive pancreatoduodenectomy.

Ann Pancreat Cancer 2019 Jan 16;2. Epub 2019 Jan 16.

Department of Surgery, University of Florida College of Medicine, Gainesville, FL, USA.

Minimally invasive approaches to abdominal surgical procedures have provided superior outcomes when compared to the open approach and thus have become the standard of care. However, minimally invasive pancreatoduodenectomy (MIPD) presents unique difficulties for both laparoscopic and robotic platforms and remains controversial. Ongoing concerns continue about the minimally invasive approach creating meaningful benefit when system-wide data may suggest MIPD results in increased morbidity and mortality during the learning curve. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/apc.2018.12.02DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7017591PMC
January 2019

Insights into the biology and treatment strategies of pancreatic neuroendocrine tumors.

Ann Pancreat Cancer 2019 Jun 20;2. Epub 2019 Jun 20.

Department of Pathology & Laboratory Medicine, Weill Cornell Medicine, New York, NY 10065, USA.

Pancreatic neuroendocrine tumors (PNETs) are the second most common primary pancreatic neoplasms after pancreatic ductal adenocarcinoma. PNETs present with widely various clinical manifestation and unfavorable survival rate. The recent advances in next generation sequencing have significantly increased our understanding of the molecular landscape of PNETs and help guide the development of targeted therapies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/apc.2019.06.02DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6750261PMC
June 2019
1 Read

Ductal acinar? Recent insights into identifying cell lineage of pancreatic ductal adenocarcinoma.

Ann Pancreat Cancer 2019 Jun 17;2. Epub 2019 Jun 17.

Department of Cell Systems and Anatomy, UT Health San Antonio, TX 78229, USA.

Pancreatic ductal adenocarcinoma (PDAC) is a deadly disease with a 5-year survival rate of less than 8%. To date, there are no early detection methods or effective treatments available. Many questions remain to be answered in regards to the pathogenesis of PDAC, among which, the controversy over the cell lineage of PDAC demands more attention. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/apc.2019.06.03DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6746423PMC
June 2019
1 Read

Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios inversely correlate to clinical and pathologic stage in patients with resectable pancreatic ductal adenocarcinoma.

Ann Pancreat Cancer 2019 Jun 11;2. Epub 2019 Jun 11.

University of Arizona Cancer Center, Tucson, AZ, USA.

Background: Post-surgical pathology (SP) staging correlates with long-term survival. Neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) have been shown to predict prognosis and extent of tumor in patients with metastatic pancreatic ductal adenocarcinoma (PDAC). This study aimed to correlate NLR and PLR to radiological clinical staging (CS), carbohydrate antigen (CA) 19-9 tumor marker and SP staging in patients with resectable-PDAC (R-PDAC); and to investigate NLR and PLR as potential markers to guide neoadjuvant therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/apc.2019.06.01DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6663083PMC
June 2019
2 Reads

Adjuvant therapeutic strategies for resectable pancreatic adenocarcinoma.

Ann Pancreat Cancer 2018 Aug 6;1. Epub 2018 Aug 6.

Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, Rutgers Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ, USA.

Of all patients diagnosed with pancreatic adenocarcinoma, only 15-20% present with resectable disease. Despite curative-intent resection, the prognosis remains poor with the majority of patients recurring, prompting the need for adjuvant therapy. Historical data support the use of adjuvant 5-fluorouracil (5-FU) or gemcitabine, but recent data suggest either gemcitabine plus capecitabine or modified FOLFIRINOX can improve overall survival when compared to gemcitabine alone. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/apc.2018.07.05DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6345263PMC
August 2018
19 Reads

Immune defects in pancreatic cancer.

Authors:
Lei Zheng

Ann Pancreat Cancer 2018 Dec 6;1. Epub 2018 Dec 6.

The Pancreatic Cancer Precision Medicine Center of Excellence Program, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Pancreatic cancer is resistant to the immunotherapy. This resistance is caused by any of the four immune "defects" that occur in pancreatic cancer, including lack of "high quality" T cells, stromal barriers to T cells getting access to tumor cells, immunosuppressive cells such as M2 macrophages, myeloid derivative suppressor cells, and T regulatory cells, in the tumor microenvironment of pancreatic cancer. One or more defects may occur in an individual pancreatic cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/apc.2018.11.01DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6319882PMC
December 2018
23 Reads

Stressing for sugar: a new role of serotonin for glycolysis in pancreatic cancer cells.

Ann Pancreat Cancer 2018 Oct 10;1. Epub 2018 Oct 10.

Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/apc.2018.09.03DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7295168PMC
October 2018

Current and emerging radiotherapy strategies for pancreatic adenocarcinoma: stereotactic, intensity modulated and particle radiotherapy.

Ann Pancreat Cancer 2018 Aug 13;1. Epub 2018 Aug 13.

Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

The role of radiotherapy for locally advanced pancreatic cancer (LAPC) is unclear based on studies that used conventional doses and fractionation schedules. Modern radiotherapy techniques have not been studied in depth, however. We reviewed the literature on emerging methods of delivering higher doses of conformal radiotherapy using stereotactic body radiation, intensity modulated radiation, and particle beam radiation, highlighting clinical outcomes and toxicities. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/apc.2018.07.03DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6124686PMC
August 2018
2 Reads

Can computational modeling help in personalizing the care of patients with pancreatic ductal adenocarcinoma?

Authors:
Efrat Dotan

Ann Pancreat Cancer 2018 May 24;1(5). Epub 2018 May 24.

Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/apc.2018.05.01DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7324040PMC

Diagnostic intervals and pancreatic ductal adenocarcinoma (PDAC) resectability: a single-center retrospective analysis.

Ann Pancreat Cancer 2018 27;1. Epub 2018 Feb 27.

Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.

Background: Pancreatic ductal adenocarcinoma (PDAC) often presents with nonspecific symptoms and the workup is not standardized. To study the impact of delays in diagnosis and in the initiation of treatment, we investigated the relationship between length of diagnostic intervals and surgical resectability.

Methods: We performed a retrospective chart review of patients evaluated for PDAC at Johns Hopkins in 2014. Read More

View Article

Download full-text PDF

Source
http://apc.amegroups.com/article/view/4014/4720
Publisher Site
http://dx.doi.org/10.21037/apc.2018.02.01DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909699PMC
February 2018
13 Reads
  • Page 1 of 1